YIH
HRTX icon

Y-Intercept (HK)’s Heron Therapeutics HRTX Stock Holding History

Y-Intercept (HK)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,629
Closed -$39.1K – 1396
2024
Q3 		$39.1K Buy
+19,629
New +$46.9K ﹤0.01% 1230
2023
Q3 		– Sell
-66,326
Closed -$76.9K – 1273
2023
Q2 		$76.9K Buy
+66,326
New +$118K 0.01% 1146
2023
Q1 		– Sell
-50,770
Closed -$127K – 1328
2022
Q4 		$127K Sell
50,770
-2,877
-5% -$9.27K 0.02% 883
2022
Q3 		$226K Buy
+53,647
New +$210K 0.02% 787
2021
Q1 		– Sell
-19,351
Closed -$412K – 688
2020
Q4 		$412K Buy
+19,351
New +$336K 0.17% 210

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Y-Intercept (HK)'s HRTX Position: Q4 2024 in Review

Y-Intercept (HK) sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 19,629 shares — an estimated $39.1K sold.

Y-Intercept (HK) first reported a position in HRTX in Q4 2020 and held it in 5 quarters. The position peaked at $412K in Q4 2020. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Y-Intercept (HK) reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 19,629 Heron Therapeutics shares in Q4 2024, an estimated $39.1K.
  • Y-Intercept (HK) first reported a position in Heron Therapeutics in Q4 2020 and held it in 5 quarters.
  • Y-Intercept (HK)'s Heron Therapeutics position peaked at $412K in Q4 2020.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Y-Intercept (HK)'s 13F filing for Q4 2024, filed 4 Feb 2025.